Physician profile
Luis Maas
NPI 1750361226
$2,838.92
in general payments reported to CMS, 2019-2025
9 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $122 · 2021: $102 · 2022: $323 · 2023: $828 · 2024: $563 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $932.63 | 2019-2024 | |
| Janssen Biotech, INC. | $590.70 | 2023-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $323.52 | 2020-2024 | Epclusa |
| Qol Medical, LLC | $233.21 | 2023-2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $212.63 | 2023-2024 | Dupixent |
| Janssen Scientific Affairs, LLC | $202.06 | 2019-2021 | |
| Dova Pharmaceuticals | $122.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $122.13 | 2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Maas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.